Cortex Pharmaceutic Stock Total Asset
| PHXDelisted Stock | USD 4.35 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess CORTEX PHARMACEUTIC's long-term financial health and intrinsic value.
CORTEX |
CORTEX PHARMACEUTIC Company Total Asset Analysis
CORTEX PHARMACEUTIC's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current CORTEX PHARMACEUTIC Total Asset | 163.92 M |
Most of CORTEX PHARMACEUTIC's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CORTEX PHARMACEUTIC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, CORTEX PHARMACEUTIC has a Total Asset of 163.92 M. This is 99.54% lower than that of the Oil, Gas & Consumable Fuels sector and 99.25% lower than that of the Energy industry. The total asset for all Germany stocks is 99.44% higher than that of the company.
CORTEX Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CORTEX PHARMACEUTIC's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CORTEX PHARMACEUTIC could also be used in its relative valuation, which is a method of valuing CORTEX PHARMACEUTIC by comparing valuation metrics of similar companies.CORTEX PHARMACEUTIC is currently under evaluation in total asset category among its peers.
CORTEX Fundamentals
| Return On Equity | 0.0555 | |||
| Return On Asset | 0.0185 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | (0.04) % | |||
| Current Valuation | 182.81 M | |||
| Shares Outstanding | 37.92 M | |||
| Shares Owned By Insiders | 15.10 % | |||
| Shares Owned By Institutions | 69.39 % | |||
| Number Of Shares Shorted | 123.3 K | |||
| Price To Earning | 21.21 X | |||
| Price To Book | 1.31 X | |||
| Price To Sales | 4.58 X | |||
| Revenue | 34.27 M | |||
| Gross Profit | 30.11 M | |||
| EBITDA | 15.32 M | |||
| Net Income | 2.32 M | |||
| Cash And Equivalents | 3.4 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 30.2 M | |||
| Debt To Equity | 0.30 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | 18.08 M | |||
| Short Ratio | 0.13 X | |||
| Earnings Per Share | 0.19 X | |||
| Target Price | 4.35 | |||
| Number Of Employees | 18 | |||
| Beta | 0.064 | |||
| Market Capitalization | 164.96 M | |||
| Total Asset | 163.92 M | |||
| Retained Earnings | 77.07 M | |||
| Working Capital | 6.32 M | |||
| Current Asset | 6.57 M | |||
| Current Liabilities | 4.47 M | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 1.88 % | |||
| Net Asset | 163.92 M | |||
| Last Dividend Paid | 0.15 |
About CORTEX PHARMACEUTIC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CORTEX PHARMACEUTIC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CORTEX PHARMACEUTIC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CORTEX PHARMACEUTIC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in CORTEX Stock
If you are still planning to invest in CORTEX PHARMACEUTIC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CORTEX PHARMACEUTIC's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |